Mr. Gorlin has 45 years of experience in the biotechnology and pharmaceutical industries. He has founded several biotechnology and pharmaceutical companies, including Medivation, Inc.; Medicis Pharmaceutical Corporation; MiMedx; DARA BioSciences, Inc.; Hycor Biomedical, Inc.; CytRx Corporation; and EntreMed, Inc. Additionally, Mr. Gorlin served for many years on the business advisory council to the Johns Hopkins School of Medicine and on the Johns Hopkins biomedical engineering advisory board, and serves on the board of Andrews Institute. Mr. Gorlin is also the founder of The Touch Foundation, a nonprofit organization for the blind, and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. In addition to his position as board chair for SmartPharm Therapeutics, he also currently serves as vice chairman of NantKwest, Inc.; chairman of ViCapsys; CEO of Nantibody Fc; and on the boards of Medovex, Inc.; Catasys, Inc.; Nantibody Fc; and NTC China, Inc. He is also a member of the Research Institute Advisory Council (RIAC) at Massachusetts General Hospital.
Prior to his retirement in 2017, Mr. Driscoll served as chief financial officer at Flexion Therapeutics, where he spearheaded a successful IPO in 2014 and during his tenure raised over $600 million toward the ultimate FDA approval of Zilretta®. From 2009 to 2013 he served as chief financial officer at Novavax, Inc., a publicly traded biopharmaceutical company. Prior to Novavax, Mr. Driscoll served as chief financial officer from 2007 to 2008, and subsequently chief executive officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company that was acquired by GlaxoSmithKline; and chief executive officer at OXiGENE, Inc., a biopharmaceutical company, from 2000 to 2006.
He began his biotechnology career serving as chief financial officer at Instrumentation Laboratory, an in vitro diagnostics company. Mr. Driscoll has served as chairman of the board at OXiGENE and as a member of the audit committee for Cynapsus Therapeutics Inc., which was sold to Sunovion Pharmaceuticals in 2016. He currently sits on the boards of Cellectar Biosciences, Cue Biopharma, MEI Pharma, and NantKwest, all publicly traded companies where he serves on the audit committees of each.
Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.
Peter C. Gerhard
Mr. Gerhard is the founder, managing partner, chief investment officer, and a portfolio manager of G Capital. Mr. Gerhard launched G Capital in 2009 after spending more than 20 years at Goldman Sachs. While at Goldman Sachs, he was named a partner in 1994 and was a member of the bank’s risk committee and also a member of the operating committee for its fixed income, currency, and commodities business. Mr. Gerhard is also the founder of Intervention Energy, LLC.
John T. Potts, MD, DSc
Dr. Potts is the Jackson Distinguished Professor of Clinical Medicine at the Massachusetts General Hospital (MGH) and Harvard Medical School. After completing his MD at the University of Pennsylvania and internship and residency at MGH, he worked at the National Institutes of Health for almost a decade, studying protein chemistry with Nobel laureate Christian Anfinsen. He returned to MGH as chief of endocrinology in 1968, where he subsequently served as director of research, chairman of the department of medicine, and physician-in-chief. An internationally recognized authority on calcium metabolism and the hormonal mechanisms that govern it, he has been a pioneer in identifying the chemistry and biology of clinical disorders of bone and mineral ion metabolism.
Dr. Potts has played an active role in the life sciences industry. He is a founder of Radius Health, Inc., a biopharmaceutical company focused on developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, where he currently serves as a scientific advisory board member. He has also served on advisory boards with MPM Capital and HealthCare Ventures. He has previously held board of director positions with Cell Genesys, Zeltiq Aesthetics, Genentech, and NantKwest.
An author on over 500 publications, his honors and awards include the Association of Professors of Medicine’s Robert H. Williams, MD, Distinguished Chair of Medicine Award; the Biomedical Science Career Program Hope Award; the Endocrine Society’s Fred Konrad Koch Award; and the American Society for Bone and Mineral Research’s William F. Neumann Award. He holds active and honorary memberships in a number of scientific and professional organizations including the National Academy of Medicine, American Academy of Arts and Sciences, and the National Academy of Sciences.
Mr. Preston is president and CEO of North American Development Group, one of the largest private developers and owners of retail shopping centers in North America. Mr. Preston has over 40 years of successful real estate development and investment experience throughout North America. Mr. Preston is also a founding partner of Centrecorp Management Services, which has become one of the largest private retail service providers in North America. In addition, he was co-founder and executive director of Centrefund Realty, a $1.1 billion Toronto Stock Exchange listed public company which, over a six-year period until it was sold in 2000, grew from a portfolio of 5 properties to own over 70 shopping centers. In 2007, Mr. Preston co-partnered the privatization of Sterling Centrecorp Inc. in a $280 million transaction. Mr. Preston, over the past few years, co-founded five investment funds in the United States and one in Canada, comprising over $1.25 billion of equity. These funds are investment partnerships comprising private and institutional investors.
Mr. Preston received his MBA from York University in Toronto.
José Trevejo, MD, PhD
Dr. Trevejo brings his experience and passion for leading research and development teams in the advancement of novel therapeutics for serious diseases. Before joining SmartPharm as CEO, Dr. Trevejo served as vice president, clinical development, at Cyclerion Therapeutics, where he helped advance a diverse clinical pipeline in rare diseases such as sickle cell anemia. Dr. Trevejo joined Ironwood/Cyclerion from Visterra, where he was a member of the executive team and lead the preclinical and clinical development of novel biologics. While at Visterra, he oversaw the transition to a clinical stage company as well as helped to secure a $215 million DHHS award to support development of a novel treatment for influenza. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, he served as instructor in medicine at Harvard Medical School and was a principal biomedical scientist at the Draper Laboratory.
Dr. Trevejo completed his clinical training at BWH/BIDMC/Harvard Medical School and earned his MD and PhD degrees from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York.